Insmed Inc Stock Buy Hold or Sell Recommendation
| INSM Stock | USD 79.38 0.54 0.68% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Insmed Inc is 'Strong Buy'. The recommendation algorithm takes into account all of Insmed's available fundamental, technical, and predictive indicators you will find on this site.
Check out Insmed Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Insmed and provide practical buy, sell, or hold advice based on investors' constraints. Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Insmed |
Execute Insmed Buy or Sell Advice
The Insmed recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Insmed Inc. Macroaxis does not own or have any residual interests in Insmed Inc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Insmed's advice using the current market data and latest reported fundamentals.
Time Horizon
30 Days |
Risk Tolerance
I am an educated risk taker |
 |  |
Strong Buy
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Insmed Trading Alerts and Improvement Suggestions
| The company reported the previous year's revenue of 363.71 M. Net Loss for the year was (913.77 M) with profit before overhead, payroll, taxes, and interest of 277.96 M. | |
| Insmed Inc currently holds about 554.87 M in cash with (683.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62. | |
| Insmed Inc has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Is Insmed Incorporated a Best Biotech Stock According to Billionaires |
Insmed Returns Distribution Density
The distribution of Insmed's historical returns is an attempt to chart the uncertainty of Insmed's future price movements. The chart of the probability distribution of Insmed daily returns describes the distribution of returns around its average expected value. We use Insmed Inc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Insmed returns is essential to provide solid investment advice for Insmed.
| Mean Return | 0.14 |
| Value At Risk | -3.26 |
| Potential Upside | 3.63 |
| Standard Deviation | 2.22 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Insmed historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Insmed Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Insmed, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Insmed Inc back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Rtw Investments, Llc | 2024-12-31 | 3 M | |
| Ameriprise Financial Inc | 2024-12-31 | 2.9 M | |
| Fidelity International Ltd | 2024-12-31 | 2.6 M | |
| William Blair Investment Management, Llc | 2024-12-31 | 2.4 M | |
| Alliancebernstein L.p. | 2024-12-31 | 2.4 M | |
| Macquarie Group Ltd | 2024-12-31 | 2.3 M | |
| Franklin Resources Inc | 2024-12-31 | 2.2 M | |
| T. Rowe Price Investment Management,inc. | 2024-12-31 | 2 M | |
| Pictet Asset Manangement Sa | 2024-12-31 | 2 M | |
| Vanguard Group Inc | 2024-12-31 | 18.2 M | |
| Blackrock Inc | 2024-12-31 | 16 M |
Insmed Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 45.3M | 184.0M | 357.3M | (591.7M) | 72.7M | 76.3M | |
| Free Cash Flow | (226.2M) | (370.6M) | (410.3M) | (549.5M) | (705.8M) | (670.5M) | |
| Depreciation | 14.2M | 14.2M | 10.3M | 10.6M | 11.0M | 11.6M | |
| Other Non Cash Items | 27.4M | 52.0M | 6.5M | 167.2M | 122.0M | 128.1M | |
| Capital Expenditures | 6.8M | 7.3M | 9.9M | 13.3M | 21.9M | 23.0M | |
| Net Income | (294.1M) | (434.7M) | (481.5M) | (749.6M) | (913.8M) | (868.1M) | |
| End Period Cash Flow | 532.8M | 716.8M | 1.1B | 482.4M | 555.0M | 582.8M | |
| Change To Inventory | (21.2M) | (17.5M) | (1.7M) | (13.6M) | (17.0M) | (17.9M) | |
| Investments | (6.8M) | (50.3M) | (34.6M) | (205.1M) | (583.2M) | (554.0M) | |
| Change Receivables | (13.7M) | 2.7M | (8.1M) | (6.4M) | (5.8M) | (6.1M) | |
| Change To Netincome | 27.0M | 36.2M | 71.0M | 46.3M | 53.2M | 28.4M |
Insmed Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Insmed or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Insmed's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Insmed stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.16 | |
β | Beta against Dow Jones | 0.84 | |
σ | Overall volatility | 2.23 | |
Ir | Information ratio | 0.08 |
Insmed Volatility Alert
Insmed Inc currently demonstrates below-average downside deviation. It has Information Ratio of 0.08 and Jensen Alpha of 0.16. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Insmed's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Insmed's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Insmed Fundamentals Vs Peers
Comparing Insmed's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Insmed's direct or indirect competition across all of the common fundamentals between Insmed and the related equities. This way, we can detect undervalued stocks with similar characteristics as Insmed or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Insmed's fundamental indicators could also be used in its relative valuation, which is a method of valuing Insmed by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Insmed to competition |
| Fundamentals | Insmed | Peer Average |
| Return On Equity | -8.91 | -0.31 |
| Return On Asset | -0.29 | -0.14 |
| Profit Margin | (2.51) % | (1.27) % |
| Operating Margin | (2.35) % | (5.51) % |
| Current Valuation | 14.17 B | 16.62 B |
| Shares Outstanding | 181 M | 571.82 M |
| Shares Owned By Insiders | 0.98 % | 10.09 % |
| Shares Owned By Institutions | 99.02 % | 39.21 % |
| Number Of Shares Shorted | 14.46 M | 4.71 M |
| Price To Earning | (8.70) X | 28.72 X |
| Price To Book | 50.66 X | 9.51 X |
| Price To Sales | 39.50 X | 11.42 X |
| Revenue | 363.71 M | 9.43 B |
| Gross Profit | 277.96 M | 27.38 B |
| EBITDA | (818.79 M) | 3.9 B |
| Net Income | (913.77 M) | 570.98 M |
| Cash And Equivalents | 554.87 M | 2.7 B |
| Cash Per Share | 4.62 X | 5.01 X |
| Total Debt | 45.49 M | 5.32 B |
| Current Ratio | 5.93 X | 2.16 X |
| Book Value Per Share | 1.59 X | 1.93 K |
| Cash Flow From Operations | (683.88 M) | 971.22 M |
| Short Ratio | 7.75 X | 4.00 X |
| Earnings Per Share | (5.57) X | 3.12 X |
| Target Price | 95.78 | |
| Number Of Employees | 1.27 K | 18.84 K |
| Beta | 1.28 | -0.15 |
| Market Capitalization | 14.37 B | 19.03 B |
| Total Asset | 2.03 B | 29.47 B |
| Retained Earnings | (4.36 B) | 9.33 B |
| Working Capital | 1.32 B | 1.48 B |
| Current Asset | 28.15 M | 9.34 B |
| Current Liabilities | 3.89 M | 7.9 B |
Note: Disposition of 18750 shares by Lewis William of Insmed at 22.76 subject to Rule 16b-3 [view details]
Insmed Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Insmed . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 43537.61 | |||
| Daily Balance Of Power | (0.20) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 80.18 | |||
| Day Typical Price | 79.91 | |||
| Price Action Indicator | (1.07) | |||
| Period Momentum Indicator | (0.54) |
About Insmed Buy or Sell Advice
When is the right time to buy or sell Insmed Inc? Buying financial instruments such as Insmed Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Insmed in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Entertainment Thematic Idea Now
Entertainment
Companies from entertainment industry including show business, news and media. The Entertainment theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Entertainment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Insmed Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share | Quarterly Revenue Growth 0.248 | Return On Assets | Return On Equity |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.